Neumora shares sink following Phase III flop in MDD

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Jan 4, 2025 - 06:00
Neumora shares sink following Phase III flop in MDD
The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow